AI Visibility for CROs: Winning Trust Before the RFP

Claims in this piece are observable and methodological — no client or benchmark data used.

A clinical development lead at a mid-sized biotech is choosing a contract research organisation for a Phase II programme in a specific therapeutic area. Often, before a single RFP goes out, a shortlist is already taking shape. It forms in conversations with colleagues, in past-sponsor relationships, in conference impressions — and, increasingly, in a research session with an AI assistant, where the lead asks which CROs have genuine depth in that indication, that patient population, that regulatory pathway. By the time the RFP is issued, much of the field of who gets invited to bid may already have narrowed.

That is the uncomfortable reality for a CRO: the RFP is frequently not the start of the competition. It is often closer to the end of an earlier one — the contest that decides who is even asked to compete. And that earlier contest is fought on something most CROs have never deliberately managed: whether an outside party researching them, before contact, can establish that they have real, specific, relevant expertise.

This article is about that pre-RFP stage, why AI-assisted research now shapes it, and what a CRO can actually do about it — without overstating, and without any promise that AI will recommend anyone.

The RFP is won or lost before it is written

Sponsors do not issue RFPs to the open market. They issue them to a shortlist — a handful of CROs judged, in advance, to be credible candidates for this specific study. Getting onto that shortlist is a distinct contest from winning the bid, and it runs on different information.

Winning the bid turns on proposal quality, pricing, the team, the relationship, and formal qualification. Getting onto the shortlist turns on something earlier and quieter: whether, when a sponsor or their team researches “CROs with real experience in [indication / phase / geography / regulatory pathway],” your organisation surfaces, and is described with enough specific, credible depth to be worth including. A CRO can be excellent at running trials and still be absent from that pre-RFP shortlist — and when that happens, one under-appreciated reason can be that it was simply hard to establish as a candidate in the research that built the list, rather than that it was weighed and rejected.

Increasingly, part of that research runs through AI assistants. A sponsor’s clinical or business-development team can ask ChatGPT, Gemini, Perplexity, Claude or Copilot to suggest CROs for a particular kind of study, and read the answer before opening a single website. What that answer can establish about you — accurately or not, specifically or vaguely — feeds the shortlist you never see being built.

Why CRO expertise is unusually hard for AI to establish

CROs have a specific version of the legibility problem, and it is worth being precise about why. The value of a CRO is largely tacit and relational: therapeutic-area judgement, investigator relationships, patient-recruitment know-how, regulatory experience, operational reliability across past programmes. Much of that lives in people, in sponsor relationships, and in confidential study history that cannot — and should not — be made public.

So the CRO faces a genuine tension. The things that most prove its expertise (specific past studies, sponsor names, outcomes) are often confidential. What remains publicly discoverable can easily collapse into generic language — “full-service CRO,” “global reach,” “therapeutic expertise across multiple areas” — which tells an outside researcher, human or AI, almost nothing about whether this CRO genuinely has depth in the specific thing a sponsor is researching. The expertise is real; the establishable evidence of it is thin. This is the same mechanism examined in When AI Recommends a CDMO, What Is It Actually Evaluating? — an AI’s account of you is a readout of your public legibility, not your actual capability — but for CROs the gap is widened by how much genuine expertise is legitimately confidential.

The four things a sponsor’s early research tries to establish

Whether the early research is done by a person or an AI assistant working from public information, it is trying to establish a small set of things about a CRO before shortlisting it. Each is something you either make legible or leave ambiguous:

• Therapeutic-area depth — that you have genuine, specific experience in this indication or class, not a generic claim to cover “multiple therapeutic areas.”
• Phase and study-type fit — that you actually run the kind of study in question (early-phase, complex Phase III, rare-disease, adaptive design, particular endpoints), stated specifically enough to match a requirement.
• Regulatory and geographic reach — that your experience covers the relevant regulatory pathways and regions (FDA, EMA, MHRA, PMDA; the geographies where the trial must run), clearly rather than by implication.
• Operational credibility — that there is discoverable, supportable evidence of how you work — capabilities, quality systems, genuine specialisation — beyond adjectives.

A CRO that makes these four legible, within the bounds of confidentiality, gives an outside researcher something specific to establish. One that presents only “full-service, global, experienced” gives an AI nothing to distinguish it from a hundred others — and so it is easy to leave off a shortlist built on specifics.

Legibility without breaching confidentiality

The obvious objection — “our best proof is confidential” — is real, and the answer is not to breach confidentiality. It is to make the establishable, non-confidential substance of your expertise clear and specific. You cannot name a sponsor or disclose a study; you can describe, accurately and without identifying anyone, the therapeutic areas where you hold genuine depth, the study types and phases you run, the regulatory pathways and geographies you operate across, and the specific capabilities that distinguish your work. That is legitimate, public, and far more useful to an outside researcher than “therapeutic expertise across multiple areas.”

The discipline here is the same honesty that governs all of Emerivo’s work: make genuine expertise legible, never manufacture or overstate it. An inflated claim of depth in an area you don’t genuinely have will fail the moment a sponsor moves from research to real evaluation — and in clinical research, that failure is expensive and reputational. The goal is accurate, specific, establishable representation of real expertise, not a better-sounding claim.

A demonstration you can run

You can observe your own pre-RFP legibility directly, in a few minutes, at no cost. Take your strongest therapeutic area and a realistic sponsor requirement, and ask ChatGPT, Gemini, Perplexity, Claude and Copilot a question a sponsor’s team might ask — for example, “Which CROs have genuine experience running [phase] trials in [therapeutic area] for [region/regulatory pathway], and what distinguishes them?”

Read the answers not for flattery, but for whether any assistant can establish your genuine depth in that area. Do you appear? Is your relevant experience described specifically, or are you flattened into a generic “full-service CRO” — or omitted while less-expert competitors are named because they made their specialisation more legible? Where an assistant cannot articulate expertise you genuinely hold, that gap is your pre-RFP exposure, visible directly. Results vary by platform, prompt and time, so treat this as reproducible observation, not proof of how any model will always behave.

The takeaway

For a CRO, the most consequential competition often happens before the RFP exists — in the research that decides who makes the shortlist. That research increasingly runs, in part, through AI assistants working from your public presence, and it rewards specific, establishable evidence of genuine therapeutic and operational depth. The CRO’s particular challenge is that much of its best proof is confidential — which makes the non-confidential legibility of its real expertise matter more, not less. You cannot disclose your way to visibility; you can make your genuine, shareable expertise clear, specific, and consistent enough that an outsider — sponsor or AI — can establish it before the shortlist is drawn. That is trust built before the RFP: not a promise of the win, but a place in the competition for it.

Emerivo is a specialist advisory for pharmaceutical manufacturing and research organisations — TPMs, CMOs, CDMOs and CROs. The AI Discovery Audit™ examines what AI assistants can currently establish about your organisation against realistic buyer questions — diagnostic, never a promise of rankings or recommendations. For the wider context, see When AI Recommends a CDMO, What Is It Actually Evaluating? and Why Some Pharmaceutical Manufacturers Are Shortlisted Before the First Sales Call.

Frequently asked questions